# Barbara Sjouke

List of Publications by Year
in descending order



| 30 | 1,753 | 394421 19 | 454955 30 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 30 | 30 | 30 | 2491 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotypeâ€“phenotype relationship, and clinical outcome. European Heart Journal, 2015, 36, 560-565. | 2.2 | 366 |
| 2 | The PCSK9 decade. Journal of Lipid Research, 2012, 53, 2515-2524. | 4.2 | 355 |
| 3 | Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 3058-3065. | 2.4 | 146 |
| 4 | Nonpharmacological Lipoprotein Apheresis Reduces Arterial Inflammation inÂFamilial Hypercholesterolemia. Journal of the American College of Cardiology, 2014, 64, 1418-1426. | 2.8 | 90 |
| 5 | Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circulation: Cardiovascular Genetics, 2015, 8, 823-831. | 5.1 | 90 |
| 6 | Exome Sequencing and Directed Clinical Phenotyping Diagnose Cholesterol Ester Storage Disease Presenting as Autosomal Recessive Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2909-2914. | 2.4 | 87 |
| 7 | Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes and Endocrinology,the, 2014, 2, 455-463. | 11.4 | 84 |
| 8 | Homozygous autosomal dominant hypercholesterolaemia. Current Opinion in Lipidology, 2015, 26, 200-209. | 2.7 | 52 |
| 9 | Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. Atherosclerosis, 2016, 248, 238-244. | 0.8 | 50 |
| 10 | Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: A European cross-sectional study. Atherosclerosis, 2015, 240, 90-97. | 0.8 | 43 |
| 11 | Familial Hypercholesterolemia: Present and Future Management. Current Cardiology Reports, 2011, 13, 527-536. | 2.9 | 40 |
| 12 | Autosomal Recessive Hypercholesterolemia. Journal of the American College of Cardiology, 2018, 71, 279-288. | 2.8 | 38 |
| 13 | Genetic variation inAPOB,PCSK9, andANGPTL3in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels. Human Mutation, 2012, 33, 448-455. | 2.5 | 36 |
| 14 | Screening and treatment of familial hypercholesterolemia â€“ Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014). Atherosclerosis, 2015, 241, 597-606. | 0.8 | 34 |
| 15 | Lipoprotein(a) Improves Cardiovascular Risk PredictionÂBased on Established Risk Algorithms. Journal of the American College of Cardiology, 2017, 69, 1513-1515. | 2.8 | 31 |
| 16 | Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia. Atherosclerosis, 2016, 251, 263-265. | 0.8 | 27 |
| 17 | Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease. Journal of Clinical Lipidology, 2016, 10, 1462-1469. | 1.5 | 25 |
| 18 | Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemiaâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1647-1650. | 2.4 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Children with hypercholesterolemia of unknown cause: Value of genetic risk scores. Journal of Clinical Lipidology, 2016, 10, 851-859. | 1.5 | 21 |
| 20 | Is mipomersen ready for clinical implementation? A transatlantic dilemma. Current Opinion in Lipidology, 2013, 24, 301-306. | 2.7 | 19 |
| 21 | Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia. Journal of Clinical Lipidology, 2017, 11, 507-514. | 1.5 | 19 |
| 22 | Clinical characteristics of primary carnitine deficiency: A structured review using a caseâ€byâ€case approach. Journal of Inherited Metabolic Disease, 2022, 45, 386-405. | 3.6 | 18 |
| 23 | Biochemical and imaging parameters in acid sphingomyelinase deficiency: Potential utility as biomarkers. Molecular Genetics and Metabolism, 2020, 130, 16-26. | 1.1 | 15 |
| 24 | The role of antibiotic prophylaxis in endoscopic retrograde cholangiopancreatography; a retrospective single-center evaluation. Scandinavian Journal of Gastroenterology, 2012, 47, 245-250. | 1.5 | 14 |
| 25 | Serum Lipids and Lipoproteins During Uncomplicated Malaria: A Cohort Study in LambarÃ©nÃ©, Gabon. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1205-1214. | 1.4 | 11 |
| 26 | The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) study. Journal of Clinical Lipidology, 2019, 13, 272-278. | 1.5 | 7 |
| 27 | Effects of mineralocorticoid receptor antagonists on the risk of thrombosis, bleeding and mortality: A systematic review and meta-analysis of randomized controlled trials. Thrombosis Research, 2016, 144, 32-39. | 1.7 | 4 |
| 28 | Effects of Supra-Physiological Levothyroxine Dosages on Liver Parameters, Lipids and Lipoproteins in Healthy Volunteers: A Randomized Controlled Crossover Study. Scientific Reports, 2017, 7, 14174. | 3.3 | 4 |
| 29 | Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia. Data in Brief, 2016, 7, 1458-1462. | 1.0 | 2 |
| 30 | Screening for lysosomal acid lipase deficiency: A retrospective data mining study and evaluation of screening criteria. Atherosclerosis, 2018, 278, 174-179. | 0.8 | 2 |